Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR2 anti-CEA CAR-T cells
- Development stage
- Phase 1
- Lead developer
- Sorrento Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intra-arterial
01
Overview
CAR2 anti-CEA CAR-T cells is a chimeric antigen receptor T cell therapy targeting carcinoembryonic antigen (CEA). This therapy involves genetically modifying a patient's T cells to express a receptor that recognizes CEA, which is widely expressed in various cancers including gastric, lung, pancreatic, breast, and colorectal cancers. The modified T cells are designed to target and kill CEA-positive cancer cells. The therapy is administered through hepatic arterial infusions using a Pressure Enhanced Delivery Device (PEDD) with low-dose systemic IL-2 support.
- Other names
- anti-CEACAM5 CAR-T cellsanti-CEACAM-5 CAR-T cellsanti-CEACAM 5 CAR-T cellsCarcinoembryonic antigen-related cell adhesion molecule 5 CAR-T cell therapyanti-CEA CAR-T
Beyond the preview
Go deeper on CAR2 anti-CEA CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR2 anti-CEA CAR-T cells.